More poor Phase III data in Alzheimer's, but Roche and AC Immune vow to persevere

30 January 2019

Basel, Switzerland-based pharma giant Roche (ROG: SIX) has announced it will shutter the CREAD I and CREAD 2 Phase III trials of the Alzheimer’s disease (AD) candidate crenezumab, based on an interim analysis which showed poor efficacy data.

Roche has been working on developing the drug with fellow Swiss firm AC Immune, which discovered the compound, under an agreement dating back to 2006.

After decades of disappointing data, many large pharma firms, such as New York’s Pfizer (NYSE: PFE), have curtailed research into Alzheimer’s. Roche, however, said it would continue its efforts in this area.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK